Overview: Cytology Reporting TestIntroduction: The Cytology Reporting Test examines cells under a microscope to diagnose cancers or infections, causing lumps or abnormal symptoms. Following 2023 CAP guidelines, it uses microscopy for high specificity, aiding in cytological screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in cytopathology for patients with suspected malignancies or infections.
Other Names: Cytology Assay, Cell Analysis Test.
FDA Status: Laboratory-developed test (LDT), meeting cytopathology standards for diagnostic accuracy.
Historical Milestone: Cytology testing began in the 1940s with Pap smear development. Advanced staining techniques emerged in the 1970s, and by the 2000s, standardized reporting systems improved accuracy.
Purpose: Diagnoses cancers or infections, guides treatment, and monitors cellular abnormalities in patients with lumps or abnormal symptoms.
Test Parameters: 1. Cytology Analysis
Pretest Condition: No fasting required. Collect smear, body fluid, or CSF at any time. Report symptoms like lumps or pain, and list relevant medical history.
Specimen: 1-2 smears (slides), 5-10 mL body fluid (sterile container), or 1-2 mL CSF (sterile container). Transport in a biohazard bag immediately.
Sample Stability at Room Temperature: Indefinite
Sample Stability at Refrigeration: Indefinite
Sample Stability at Frozen: Indefinite
Medical History: Document lumps, pain, or history of cancer/infections. Include current medications or recent procedures.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for further diagnostic procedures.
Procedural Considerations: Uses microscopy with staining (e.g., Papanicolaou) to examine cells. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or improper fixation can affect results. Contamination may cause misinterpretation.
Clinical Significance: Abnormal cells confirm cancer or infection, prompting treatment. Normal results may require repeat testing or biopsy.
Specialist Consultation: Consult a pathologist or oncologist for result interpretation.
Additional Supporting Tests: Biopsy, flow cytometry, or molecular testing to confirm diagnosis.
Test Limitations: False negatives may occur with low cell yield. Results require clinical correlation.
References: CAP Cytology Guidelines, 2023; Archives of Pathology, Cibas ES, 2022.
